



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

**BCN AdvantageSM HMO-POS
BCN Advantage Group Comprehensive Formulary
Prior Authorization/ Step Therapy Program
2022 Plan Year
Updated 12/1/2021**

BCN Advantage HMO-POS Group monitors the use of certain medications to ensure our members receive the most appropriate and cost-effective drug therapy. **Prior authorization** (PA) for these drugs means that either clinical and/or administrative criteria must be met before coverage is provided. Drugs subject to **step therapy** (ST) may require previous treatment with one or more formulary drugs prior to coverage. Drugs that must meet clinical/administrative criteria are identified in the formulary list with (PA) or (ST). If drugs listed below have a **(g)** noted, the **PA** or **ST** criteria may also apply to the generic version of the drug. In some cases, the brand name drug is listed for reference and the generic drug is covered. Please refer to the Formulary to verify if your drugs are covered. Your physician can contact our pharmacy help desk to request prior authorization or step therapy for these drugs.

The clinical criteria for authorization are based on current medical information and the recommendations of the Blues' Pharmacy and Therapeutics Committee, a group of physicians, pharmacists and other experts.

Please call the customer service number on the back of your BCN Advantage member ID card if you have questions about your drug coverage or a drug claim.

MEDICATION/DRUG CLASS	CRITERIA
Abilify Maintena® (aripiprazole)	Coverage requires trial of oral aripiprazole. <u>Coverage duration:</u> Lifetime.
Actemra® Subcutaneous (tocilizumab)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Adempas® (riociguat)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Afinitor® (g) (everolimus)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Afinitor Disperz® (everolimus)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Alecensa® (alectinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/DRUG CLASS	CRITERIA
<p>Alpha-1 Proteinase Inhibitors Prolastin-C® Zemaira®</p>	<p>Coverage requires documentation of a diagnosis of necrotizing panniculitis or alpha-1 antitrypsin deficiency with an FEV1 less than or equal to 65% predicted. Coverage also requires documentation of a congenital deficiency of alpha-1 antitrypsin, demonstrated by a homozygous phenotype of AAT, and must have symptomatic emphysema.</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Age restrictions:</u> Patients 18 years of age or older.</p> <p><u>Coverage duration:</u> 1 year.</p>
<p>Alunbrig™ (brigatinib)</p>	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>

MEDICATION/DRUG CLASS	CRITERIA
Ampyra® (g) (dalfampridine)	<p><u>Initial</u> requests require documentation of a 25 foot timed walk test.</p> <p><u>Renewal</u> of therapy requires documentation that the member has shown an improvement in walking distance of a 25 foot timed walk test compared to pretreatment.</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Prescriber restrictions:</u> Prescribing physician is a neurologist.</p> <p><u>Exclusion criteria:</u> Patients with a history of seizure or moderate to severe renal impairment defined by a CrCl of 50ml/min or less.</p> <p><u>Coverage duration:</u> Initial approval is for 3 months. Reauthorization is for 1 year.</p>
Anabolic Steroids Oxandrin® (g) (oxandrolone)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Exclusion criteria:</u> Coverage will not be provided if anabolic steroids are used to enhance athletic performance or for anti-aging purposes.</p> <p><u>Coverage duration:</u> 1 year.</p>
Anticonvulsants Oxtellar XR® (oxcarbazine)	<p>Coverage requires trial or intolerance to at least 2 generic anticonvulsants.</p> <p><u>Coverage duration:</u> Lifetime.</p>
Antidepressants Trintellix® (voritoxetine) Desvenlafaxine ER Fetzima™ (levomilnacipran) Fetzima™ titration pack (levominacipran) Viibryd® (vilazodone HCl)	<p>Coverage requires the trial of at least 2 formulary generic antidepressants.</p> <p><u>Coverage duration:</u> Lifetime.</p>

MEDICATION/DRUG CLASS	CRITERIA
Antipsychotic Agents Caplyta ® (lumateperone) Latuda ® (lurasidone) Lybalvi ™ (olanzapine/samidorphan) Saphris ® (asenapine) Secuado ® (asenapine) Vraylar ™ (cariprazine) Zyprexa ® Relprevv ™ (olanzapine)	Coverage requires that the member has had a trial of at least one generic antipsychotic agent. <u>Coverage duration:</u> Lifetime.
Apidra ® (insulin glulisine)	Coverage requires the trial or intolerance to Novolog® 70/30 or Novolog®. <u>Coverage duration:</u> Lifetime.
Arcalyst ® (rilonacept)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Arikayce ® (amikacin liposome inhalation suspension)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Aristada ™ (aripiprazole lauroxil)	Coverage requires trial or intolerance to Abilify Maintena or oral aripiprazole. <u>Coverage duration:</u> Lifetime.
Aristada Initio ™ (aripiprazole lauroxil)	Coverage requires trial of oral aripiprazole. <u>Coverage duration:</u> Lifetime.
Aubagio ® (teriflunomide)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Auryxia® (ferric citrate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Avonex® (interferon beta-1a)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Ayvakit™ (avapritinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Balversa™ (erdafitinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Berinert® (C1 inhibitor, human)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Betaseron® (interferon beta-1b)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Blenrep (belantamab mafodotin-blmf)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Bosulif® (bosutinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Braftovi™ (encorafenib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Briviact® (brivaracetam)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Bronchitol® (mannitol)	Coverage requires documentation that the member has passed the Bronchitol® tolerance test. <i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Brukinsa™ (zanubrutinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Cablivi® (caplacizumab-yhdp)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Cabometyx™ (cabozantinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Calquence® (acalabrutinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Cayston® (aztreonam)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Cholbam® (cholic acid)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> Lifetime.</p>
Cimzia® (certolizumab pegol)	<p>Coverage will be provided for the diagnosis of rheumatoid arthritis when there has been a trial of two of the following preferred agents: tocilizumab (Actemra®) SC, etanercept (Enbrel®), adalimumab (Humira®), or tofacitinib (Xeljanz®/Xeljanz® XR).</p> <p>Coverage will be provided for the diagnosis of ankylosing spondylitis when there has been a trial of two of the following preferred agents: secukinumab (Cosentyx®), etanercept (Enbrel®), or adalimumab (Humira®).</p> <p>Coverage will be provided for the diagnosis of psoriatic arthritis when there has been a trial of two of the following preferred agents: secukinumab (Cosentyx®), etanercept (Enbrel®), adalimumab (Humira®), apremilast (Otezla®), ustekinumab (Stelara®), or tofacitinib (Xeljanz®/Xeljanz® XR).</p> <p>Coverage will be provided for the diagnosis of Crohn's disease when there has been a trial of adalimumab (Humira®) or ustekinumab (Stelara®).</p> <p>Coverage will be provided for the diagnosis of moderate to severe plaque psoriasis when there has been a trial of two of the following preferred agents: secukinumab (Cosentyx®), etanercept (Enbrel®), adalimumab (Humira®), ustekinumab (Stelara®), or apremilast (Otezla®).</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>

MEDICATION/DRUG CLASS	CRITERIA
Cometriq® (cabozantinib s-malate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Copaxone® (glatiramer acetate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Copiktra™ (duvelisib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Cosentyx® (secukinumab)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Cotellic™ (cobimetinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Crinone® (progesterone)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Danyelza® (naxitamab-gqgk)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Daurismo™ (glasdegib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Diacomit® (stiripentol)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Dojolvi™ (triheptanoin)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Doptelet® (avatrombopag)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Dovonex® (g) (calcipotriene)	Coverage requires the trial of at least one generic topical steroid. All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Enbrel® (etanercept)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Enhertu® (fam-trastuzumab deruxtecan-nxki)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Enspryng™ (satralizumab-mwge)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Epclusa® (sofosbuvir/velpatasvir)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> Criteria will be applied consistent with current AASLD/IDSA guidance.

MEDICATION/DRUG CLASS	CRITERIA
Epidiolex[®] (cannabidiol)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Erivedge[®] (vismodegib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Prescribers restrictions:</u> Prescribing physician is an oncologist or dermatologist. <u>Coverage duration:</u> 1 year.
Erleada[™] (apalutamide)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage Duration:</u> 1 year.
Erythropoiesis Stimulating Agents Aranesp[®] (darbepoetin), Epogen[®] (epoetin alfa), Procrit[®] (epoetin alfa)	Erythropoiesis stimulating agents are subject to Part B versus Part D review. <i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 3 months.
Esbriet[®] (pirfenidone)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Evryssi[™] (risdiplam)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Exkivity[™] (mobocertinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Extavia® (Interferon beta-1B)	Coverage requires trial of at least one of the following: Interferon Beta-1B (Betaseron®), Interferon Beta-1A (Avonex®), Peginterferon Beta-1A (Plegridy®) or Interferon Beta-1A (Rebif®) <i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Farydak® (panobinostat)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Fintepla® (fenfluramine)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Firazyr® (g) (icatibant acetate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Age restrictions:</u> Patients 18 years of age and older. <u>Coverage duration:</u> 1 year.
Firdapse® (amifampridine)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Forteo® (teriparatide)	<p>Coverage requires documentation of bone mineral density that is 2.5 standard deviations or more below the mean (T-score at or below -2.5).</p> <p>Coverage also requires that the patient has tried and failed at least one bisphosphonate except when: 1. There is a contraindication to an oral and intravenous bisphosphonate (such as a stricture or aclasia, inability to stand or sit upright for at least 30 minutes and increased risk of aspiration). 2. There is documented intolerance to a bisphosphonate.</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Fotivda® (tivozanib)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Galafold™ (migalastat)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Gamifant® (emapalumab-lzsg)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Gattex® (teduglutide)	<p>Coverage requires documentation of dependence on parenteral support for 12 months or greater.</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>

MEDICATION/DRUG CLASS	CRITERIA
Gavreto™ (pralsetinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> Coverage duration: 1 year.
Gilenya® (fingolimod hydrochloride)	<i>All medically accepted indications not otherwise excluded from Part D.</i> Coverage duration: 1 year.
Gilotrif® (afatinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> Coverage duration: 1 year.
Gleevec® (g) (imatinib mesylate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> Coverage duration: 1 year.
Growth Hormone (somatropin), Humatrope®, Norditropin®, Nutropin®, Omnitrope®, Serostim®	<i>All medically accepted indications not otherwise excluded from Part D.</i> Prescriber restrictions: For pediatric patients, all indications must be prescribed by a pediatric endocrinologist or pediatric nephrologist. Coverage duration: Pediatrics: 1 year, Adults: Lifetime.
Haegarda® (C1 Inhibitor, Human)	<i>All medically accepted indications not otherwise excluded from Part D.</i> Age restrictions: Patients 6 years of age and older. Coverage duration: 1 year.
Harvoni™ (ledipasvir/sofosbuvir)	<i>All medically accepted indications not otherwise excluded from Part D.</i> Coverage duration: Criteria will be applied consistent with current AASLD/IDSA guidance.

MEDICATION/DRUG CLASS	CRITERIA
Hemady™ (dexamethasone)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Hetlioz™ (tasimelteon)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Humalog® (insulin lispro) Humalog® Mix Insulin (Insulin Lispro Protamine-Insulin Lispro)	Coverage requires the trial of or intolerance to Novolog® 70/30 or Novolog®. <u>Coverage duration:</u> Lifetime.
Humira® (adalimumab)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Humulin® Insulin (Humulin® R, Humulin® N, Humulin® 70/30)	Coverage requires a trial of or intolerance to Novolin® 70/30, Novolin® N or Novolin® R. <u>Coverage duration:</u> Lifetime.
Ibrance® (palbociclib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Iclusig® (ponatinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Idhifa® (enasidenib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Ilaris® (canakinumab)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Imbruvica™ (ibrutinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Increlex® (mecasermin)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Inlyta® (axitinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Inqovi® (decitabine and cedazuridine)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Inrebic® (fedratinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Intranasal Steroids Omnaris® (ciclesonide)	Coverage requires a claim for 30 days of a generic nasal steroid spray or Beconase AQ in the past 120 days. <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Invega Hafyera™ (paliperidone palmitate)	Coverage requires the trial of a once-a-month paliperidone palmitate extended-release injectable suspension for at least 4 months, or an every-three-month paliperidone palmitate extended-release injectable suspension for at least one three-month cycle. <u>Coverage duration:</u> Lifetime.
Invega Sustenna® (paliperidone palmitate)	Coverage requires the trial of oral paliperidone or oral risperidone. <u>Coverage duration:</u> Lifetime.
Invega Trinza™ (paliperidone palmitate)	Coverage requires the trial of oral paliperidone or oral risperidone. <u>Coverage duration:</u> Lifetime.
Jakafi® (ruxolitinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Prescriber restriction:</u> Prescribing physician is an oncologist, hematologist, or transplant specialist. <u>Coverage duration:</u> 1 year.
Jemperli (dostarlimab-gxly)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Jynarque™ (tolvaptan)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Kalydeco™ (ivacaftor)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/DRUG CLASS	CRITERIA
Kineret® (anakinra)	Coverage for the diagnosis of rheumatoid arthritis requires a trial of two of the following preferred agents: tocilizumab (Actemra®) SC, etanercept (Enbrel®), adalimumab (Humira®), or tofacitinib (Xeljanz®/Xeljanz® XR). <i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Kisqali® (ribociclib) Kisqali® Femara® Co-Pack (ribociclib & letrozole)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Korlym™ (mifepristone)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Koselugo™ (selumetinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Lenvima™ (lenvatinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Libtayo® (cemiplimab-rwlc)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Lidoderm® Patch (g) (lidocaine)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Lonsurf® (trifluridine and tipiracil)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Lorbrena® (lorlatinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Lotronex® (g) (alosetron)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Lumakras™ (sotorasib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Lumoxiti™ (moxetumomab pasudotox-tdfk)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Lynparza™ (olaparib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Megace® (g) (megestrol)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Mekinist™ (trametinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/ DRUG CLASS	CRITERIA
Mektovi® (binimetinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Monjuvi™ (tafasitamab-cxix)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Movantik™ (naloxegol oxalate)	Coverage is provided for diagnosis of opioid induced chronic constipation with chronic, non-cancer pain. Member must be stable on opioid therapy for a minimum of 2 weeks. <i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Age restrictions:</u> Patients 18 years of age or older. <u>Coverage duration:</u> Initial=3 months Renewal=1 year
Myalept® (metreleptin)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Prescriber restrictions:</u> Prescribing physician is an endocrinologist. <u>Coverage duration:</u> 1 year.
Narcolepsy Agents Nuvigil® (g) (armodafinil) Provigil® (g) (modafanil)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/DRUG CLASS	CRITERIA
Narcotic analgesics (fentanyl citrate) Actiq® (g) Fentora® Lazanda® Subsys™	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Natpara® (parathyroid hormone, recombinant)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Nerlynx™ (neratinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Nexavar® (sorafenib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Ninlaro® (ixazomib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Nityr™ (nitisinone)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Nubeqa™ (darolutamide)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Nuedexta® (dextromethorphan hydrobromide/quinidine sulfate)	<i>All medically accepted indications not otherwise excluded from art D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/DRUG CLASS	CRITERIA
Nuplazid™ (pimavanserin)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Odomzo® (sonidegib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Ofev® (nintedanib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Onureg® (azacitidine)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Orencia® (abatacept)	<p>Coverage for the diagnosis of rheumatoid arthritis requires trial of two of the following preferred agents: tocilizumab (Actemra®) SC, etanercept (Enbrel®), adalimumab (Humira®), or tofacitinib (Xeljanz®/Xeljanz® XR).</p> <p>Coverage for the diagnosis of juvenile idiopathic arthritis requires trial of two of the following preferred agents: tocilizumab (Actemra®) SC, etanercept (Enbrel®) or adalimumab (Humira®).</p> <p>Coverage for the diagnosis of psoriatic arthritis requires trial of two of the following preferred agents: secukinumab (Cosentyx®), etanercept (Enbrel®), adalimumab (Humira®), apremilast (Otezla®), ustekinumab (Stelara®), tofacitinib (Xeljanz®/Xeljanz® XR).</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Orenitram ER™ (treprostinil diolamine)	<p>Coverage is provided for the diagnosis of pulmonary arterial hypertension. Requires trial and failure or contraindication to inhaled treprostinil and sildenafil.</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> Lifetime.</p>
Orgovyx™ (relugolix)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Orkambi® (ivacaftor/lumacaftor)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> Lifetime.</p>

MEDICATION/DRUG CLASS	CRITERIA
Otezla® (apremilast)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Oxbryta™ (voxelotor)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Oxervate™ (cenegermin-bkbj)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Padcev™ (enfortumab vedotin-ejfv)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Palynziq™ (pegvaliase-pqpz)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Pemazyre™ (pemigatinib)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Perseris™ (risperidone)	Coverage requires a trial of oral risperidone. <u>Coverage duration:</u> Lifetime.
Piqray® (alpelisib)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Plegridy® (peginterferon beta-1a)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Polivy™ (polatuzumab vedotin)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Pomalyst® (pomalidomide)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> Lifetime.</p>
Praluent® (alirocumab)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Prolia® (denosumab)	<p>Prolia® is subject to Part B versus Part D review.</p> <p>Coverage requires the patient has tried and failed at least one bisphosphonate except when: 1. There is a contraindication to an oral and intravenous bisphosphonate (such as a stricture or aclasia, inability to stand or sit upright for at least 30 minutes and increased risk of aspiration), 2. There is a documented intolerance to a bisphosphonate.</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Exclusion criteria:</u> Coverage is not provided for a diagnosis of hypocalcemia.</p> <p><u>Coverage duration:</u> 1 year.</p>

MEDICATION/DRUG CLASS	CRITERIA
Promacta® (eltrombopag)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Pulmonary Arterial Hypertension (PAH) agents Adcirca® (g) (alyq™, tadalafil), Letairis® (g) (ambrisentan), Opsumit® (macitentan), Revatio® (g) (sildenafil citrate), Tracleer® (g) (bosentan)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Exclusion criteria:</u> Coverage is not provided for sildenafil and tadalafil in situations where patients are receiving nitrate therapy. <u>Coverage duration:</u> 1 year.
Qinlock™ (ripretinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Ravicti® (glycerol phenylbutyrate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Rebif® (interferon beta-1a)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/DRUG CLASS	CRITERIA
Relistor® (methylalthrexone)	All medically accepted indications not otherwise excluded from Part D. <u>Age restrictions:</u> Patients 18 years of age or older. <u>Exclusion criteria:</u> Coverage is not provided for patients with known or suspected mechanical gastrointestinal obstruction. <u>Coverage duration:</u> 3 months.
Repatha® (evolocumab)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Retevmo™ (selpercatinib)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Revcovi™ (elapegademase-lvlr)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Revlimid® (lenalidomide)	All medically accepted indications not otherwise excluded from Part D. <u>Prescriber restrictions:</u> Must be prescribed by an oncologist or hematologist. <u>Coverage duration:</u> 1 year.
Rexulti® (brexpiprazole)	Coverage requires trial or intolerance to Abilify Maintena or oral aripiprazole. <u>Coverage duration:</u> Lifetime.
Risperdal Consta® (risperidone)	Coverage requires the trial of oral risperidone. <u>Coverage duration:</u> Lifetime.

MEDICATION/ DRUG CLASS	CRITERIA
Rozlytrek™ (entrectinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Rubraca™ (rucaparib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Ruzurgi® (amifampridine)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Rybrevant™ (amivantamab-vmjw)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Rydapt® (midostaurin)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Rylaze™ (asparaginase erwinia chrysanthemi- rywn)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Samsca® (g) (tolvaptan)	Coverage requires documentation that the member does not have underlying liver disease. <i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 month.

MEDICATION/ DRUG CLASS	CRITERIA
Sarclisa® (isatuximab-irfc)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Savella® (milnacipran)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Simponi® (golimumab)	<p>Coverage is provided for the diagnosis of rheumatoid arthritis when there has been a trial of two of the following preferred agents: tocilizumab (Actemra®) SC, etanercept (Enbrel®), adalimumab (Humira®), tofacitinib (Xeljanz®/Xeljanz® XR).</p> <p>Coverage is provided for the diagnosis of ankylosing spondylitis when there has been a trial of two of the following preferred agents: csecukinumab (Cosentyx®), etanercept (Enbrel®), adalimumab (Humira®).</p> <p>Coverage is provided for the diagnosis of psoriatic arthritis when there has been a trial of two of the following preferred agents: secukinumab (Cosentyx®), etanercept (Enbrel®), adalimumab (Humira®), apremilast (Otezla®), ustekinumab (Stelara®), or tofacitinib (Xeljanz®/Xeljanz® XR).</p> <p>Coverage is provided for the diagnosis of ulcerative colitis when there has been a trial of adalimumab (Humira®) or tofacitinib (Xeljanz®).</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <u>Coverage duration:</u> 1 year.
Sirturo™ (bedaquiline fumarate)	<p>Coverage is provided when used in combination with at least 3 other agents.</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Somavert® (pegvisomant)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Sovaldi® (sofosbuvir)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Criteria will be applied consistent with current AASLD/IDSA guidance.
Sprycel® (dasatinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Stelara® (ustekinumab)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Sutent® (sunitinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Prescriber restrictions:</u> Prescribing physician must be an oncologist. <u>Coverage duration:</u> 1 year.
Tabrecta™ (capmatinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Tafinlar® (dabrafenib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Tagrisso™ (osimertinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/DRUG CLASS	CRITERIA
Taltz® (ixekizumab)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Talzenna™ (talazoparib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Tarceva® (g) (erlotinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Prescriber restrictions:</u> Must be prescribed by an oncologist. <u>Coverage duration:</u> 1 year.
Targretin® (g) (bexarotene)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Prescriber restrictions:</u> Must be prescribed by an oncologist or dermatologist. <u>Coverage duration:</u> 1 year.
Tasigna® (nilotinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Tazverik™ (tazemetostat)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Tecfidera™ (g) (dimethyl fumarate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/DRUG CLASS	CRITERIA
Tegsedi™ (inotersen)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Tepmetko® (tepotinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Testosterone AndroGel® (g) (testosterone) Axiron® (g) (testosterone) Fortesta® (g) (testosterone) Vogelxo® (g) (testosterone)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Thalomid® (thalidomide)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Tibsovo® (ivosidenib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Tivdak™ (tisotumab vedotin-tftv)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Trikafta™ (elexacaftor/tezacaftor/ivacaftor)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Trodelvy™ (sacituzumab govitecan-hziy)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Truseltiq™ (infigratinib)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Tukysa™ (tucatinib)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Turalio™ (pexidartinib)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Ubrovelvy™ (ubrogepant)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Ukoniq™ (umbralisib)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
Uloric® (g) (febuxostat)	Coverage requires trial or contraindication of allopurinol. <u>Coverage duration:</u> Lifetime.
Uptravi® (selexipag)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.
VecamyI™ (mecamylamine)	All medically accepted indications not otherwise excluded from Part D. <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Venclexta™ (venetoclax)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Verzenio™ (abemaciclib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Vitrakvi® (larotrectinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Vizimpro® (dacomitinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Vosevi® (sofosbuvir/velpatasvir/voxilaprevir)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Criteria will be applied consistent with current AASLD/IDSA guidance.
Votrient® (pazopanib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Prescriber restrictions:</u> Must be prescribed by an oncologist. <u>Coverage duration:</u> 1 year.
Vyndamax™ (tafamidis)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Vyndaqel® (tafamidis meglumine)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Welireg™ (belzutifan)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Xalkori® (crizotinib)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Xcopri® (cenobamate)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Xeljanz®, Xeljanz® XR (tofacitnib citrate)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>
Xenazine® (g) (tetrabenazine)	<p>Documentation of the CYP2D6 genotype of the patient will be required for doses above 50mg per day.</p> <p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Exclusion criteria:</u> Coverage will not be provided in the following situations, 1) Patients with hepatic function impairment, 2) Patients who are actively suicidal or who have untreated or inadequately treated depression, 3) Patients taking monoamine oxidase inhibitors or reserpine.</p> <p><u>Coverage duration:</u> 1 year.</p>
Xermelo® (telotristat ethyl)	<p><i>All medically accepted indications not otherwise excluded from Part D.</i></p> <p><u>Coverage duration:</u> 1 year.</p>

MEDICATION/DRUG CLASS	CRITERIA
Xgeva® (denosumab)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Xolair® (omalizumab)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Xospata® (gilteritinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Xpovio™ (selinexor)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Xtandi® (enzalutamide)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Xyrem® (sodium oxybate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Exclusion criteria:</u> Coverage is not provided for patients taking sedative hypnotics or in patients with succinic semialdehyde dehydrogenase deficiency <u>Coverage duration:</u> 1 year.
Yonsa® (abiraterone acetate)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Zejula™ (niraparib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.

MEDICATION/DRUG CLASS	CRITERIA
Zelboraf® (vemurafenib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Exclusion criteria:</u> Coverage will not be provided in combination with Yervoy®. <u>Coverage duration:</u> 1 year.
Zenpep® (pancrelipase delayed release)	Coverage requires trial or intolerance to Creon®. <u>Coverage duration:</u> Lifetime.
Zepzelca™ (lurbinectedin)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Zokinvy™ (lonafarnib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Zolinza® (vorinostat)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverate duration:</u> 1 year.
Zydelig™ (idelalisib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.
Zykadia™ (ceritinib)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> Lifetime.
Zynlonta™ (loncastuximab tesirine-lpyl)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.

MEDICATION/DRUG CLASS	CRITERIA
Zytiga® (g) (abiraterone)	<i>All medically accepted indications not otherwise excluded from Part D.</i> <u>Coverage duration:</u> 1 year.